From Cancer Drugs to Fire Safety: BGMS's Radical Corporate Rebirth

KUALA LUMPUR, MALAYSIA – March 30, 2026 – Bio Green Med Solution, Inc. (NASDAQ: BGMS) today confirmed one of the most dramatic corporate transformations in recent memory, detailing a complete strategic pivot away from its origins as a biopharmaceutical firm to a new life in the fire safety and distribution industry. The company's full-year 2025 financial results, released today, paint a picture of a business in the midst of a radical rebirth, having shed its high-cost drug development operations in favor of a new venture centered on its recent acquisition of Malaysian fire protection specialist, Fitters Sdn. Bhd.

Once known as Cyclacel Pharmaceuticals, a company dedicated to developing treatments for advanced cancers, BGMS has now fully embraced its new identity. The financial statements reflect this sea change: research and development expenses have been virtually eliminated, and the first revenues from the sale of fire safety equipment have appeared on the books, marking the start of a completely new chapter for the company and its investors.

A Pivot Born from Financial Pressure

The decision to abandon the costly and uncertain world of biotechnology was not made in a vacuum. The company, as Cyclacel Pharmaceuticals, had been facing severe financial headwinds. By late 2024, it was grappling with recurring operating losses and dwindling cash reserves that threatened its ability to continue operations. The high-stakes game of drug development, with its lengthy clinical trials and massive capital requirements for candidates like fadraciclib and plogosertib, had become unsustainable.

This led to a strategic overhaul that began with a change of control and the appointment of Datuk Dr. Doris Wong Sing EE as Chief Executive Officer in early 2025. Under new leadership, the company acted swiftly. The expensive fadraciclib program was discontinued, and its U.K. subsidiary, Cyclacel Limited, was liquidated. The final tie to its pharmaceutical past was severed in October 2025 with the sale of its remaining drug asset, Plogosertib, to Tethra Biosciences for an initial $300,000.

“2025 was a productive year for BGMS, marked by the acquisition of Fitters Sdn. Bhd., a fire safety materials and equipment company, on September 12, 2025, the liquidation of our U.K. subsidiary and the sale of our Plogosertib drug, transactions which strengthened our balance sheet,” said Datuk Dr. Doris Wong Sing EE in the company's official announcement. “We used this momentum to chart our new focus towards continued growth in the company.”

Swapping R&D Costs for Fire Safety Revenue

The financial results for 2025 starkly illustrate this strategic shift. Research and development (R&D) expenses, which stood at a hefty $6.7 million in 2024, plummeted to just $0.8 million in 2025. For the final quarter of the year, R&D costs were effectively zero. In their place, a new revenue line appeared: product revenue from the sale of fire safety equipment, which totaled $0.7 million for the period following the September acquisition of Fitters Sdn. Bhd.

This fundamental change in the business model had a dramatic effect on the bottom line. BGMS reported a net loss of $3.0 million for 2025, a significant improvement from the $11.2 million net loss recorded in 2024. The improvement was aided by a one-time gain of $4.9 million from the deconsolidation of its former U.K. subsidiary. The company's total assets also grew, from $4.1 million at the end of 2024 to $8.2 million at the end of 2025, reflecting the addition of inventory, receivables, and goodwill from the Fitters acquisition.

A New Battlefield: Malaysia's Fire Protection Market

With its pivot, BGMS has traded the global biopharmaceutical landscape for the regional fire safety market in Southeast Asia. Its new core, Fitters Sdn. Bhd., is no startup. Established in 1982, Fitters is a well-regarded "one-stop" fire protection specialist in Malaysia, supplying a wide range of equipment from fire extinguishers to advanced fire-resistant doors.

The market BGMS has entered is substantial. Malaysia's fire protection system market is valued at over USD 1 billion and is projected to see steady growth. This demand is fueled by rapid urbanization, a robust construction sector, and increasingly stringent government safety mandates, such as the Fire Services Act 1988, which requires comprehensive fire safety measures in designated buildings. This regulatory environment creates a recurring need for certified products and services, potentially offering a more stable and predictable revenue stream than the boom-or-bust nature of drug discovery.

However, the market is not without its challenges. BGMS faces intense competition from both local players and established global brands. The company's initial results also reveal a concentration risk, with its top four customers accounting for 55% of its 2025 fire safety sales, a dependency it will need to mitigate as it seeks to expand its market share.

Lingering Doubts and Investor Skepticism

Despite the improved net loss and the promise of a new growth industry, significant concerns cloud the company's future. The market has reacted with extreme skepticism, with BGMS's stock price plummeting by over 98% in the past year, reducing its market capitalization to a mere $4.9 million. In its own filings, the company acknowledges there is "substantial doubt" about its ability to continue as a going concern without securing additional capital.

As of December 31, 2025, BGMS held $3.5 million in cash and cash equivalents, which it estimates will only fund its planned expenditures into the third quarter of 2026. This limited cash runway puts immense pressure on the new fire safety business to quickly become self-sustaining and profitable.

Furthermore, while the operating loss narrowed, the net loss applicable to common shareholders swelled to $14.1 million for the year. This was primarily due to a non-cash deemed dividend of $11.0 million related to a warrant exchange agreement, a complex financial maneuver that has diluted existing shareholders. For investors who once bet on a breakthrough cancer drug, the transition to a lower-margin industrial distribution model represents a fundamental and perhaps unwelcome change in their investment thesis. The company's ability to successfully navigate this new competitive landscape and secure the necessary funding to fuel its growth will be the ultimate test of this audacious corporate reinvention.